Architecture & Technology

Proprietary Analytics. Secure Data Governance. Sustainable Economics. Independent Clinical Judgment.

RDDT combines proprietary rare disease search methodologies, longitudinal clinical data analysis, and independent clinical review within a secure, governed architecture. Its outcome-independent economic model supports authorized population-wide analytics and defined Clinical Evaluation & Reconciliation Services at fair market value. Together, these capabilities create sustainable value and clinical capacity for healthcare organizations while protecting patient privacy and preserving physician independence.

Purpose-Built for Rare Disease. Governed for Clinical Independence. Designed for Scale.

Contact Us

RDDT provides U.S. healthcare organizations with Rare Disease Patient Analytic Services, which combine compliant patient-first funding, proprietary analytics, independent clinical review, and patient-consented, physician-directed evaluation to create new, sustainable revenue for healthcare organizations while advancing earlier recognition and diagnosis of previously unsuspected rare disease patients for whom potentially life-saving FDA-approved therapies already exist, within their existing healthcare systems.

Proprietary Rare Disease Intelligence

RDDT combines disease-specific search methodologies with longitudinal clinical analysis to surface high-confidence suspect patients whose conditions may have remained unrecognized for years. Its independently developed methodologies may be refined using authorized, documented clinical evaluation findings and performance reporting.

Transformative Economic Architecture

RDDT's economic model compensates healthcare organizations for authorized population-wide analytics and defined Rare Disease Patient Analytic Services at fair market value, independent of clinical outcomes. This creates sustainable economic value and supports the organizational capacity to pursue patients who might otherwise remain invisible.

Independent Clinical Judgment

RDDT operates as a neutral intermediary, with independent clinical SME review and healthcare organization governance. Physicians retain exclusive authority over evaluation, diagnosis, testing, and treatment. Neither RDDT nor its biopharma sponsors direct clinical decisions or have a financial interest in particular patient outcomes.

Secure Data Governance

Healthcare organizations retain control over patient identity, data authorization, and re-identification. RDDT conducts approved analyses of de-identified clinical data within its secure, controlled environment, returning prioritized findings for independent clinical review. Patient identity remains within the healthcare organization, and biopharmaceutical sponsors receive no patient-level clinical data.

01 / THE ARCHITECTURE

Built for Permission.                        Designed for Independence.

The governance and economic structure that makes clinical action sustainable.

Independence by Design

The Neutral Intermediary

RDDT operates independently of healthcare organizations and biopharmaceutical manufacturers. Neither sector owns or controls RDDT, nor does RDDT hold ownership interests in either. Our independence is structural, clinical, and economic.

BioPharma funds defined services at fair market value, independent of patient outcomes. RDDT has no financial interest in testing, treatment, prescribing, referrals, enrollment, or any predetermined diagnosis. Healthcare organizations and their physicians retain complete clinical authority.

This neutrality enables RDDT to deliver comprehensive, unbiased clinical dossiers based on relevant available evidence, without favoring any manufacturer, therapy, or predetermined conclusion.

Our independence protects the patient, preserves physician judgment, and makes compliant collaboration between healthcare and biopharma possible.

Compass representing RDDT's neutral intermediary position

Neutral by design

Structural. Clinical. Economic.

Independence is not simply a policy. It is built into how RDDT is organized, funded, and governed.

01

Institutional Control of Patient Data

Healthcare organizations retain authority over patient identity, data permissions, and clinical governance.

02

Independent Clinical Judgment

Qualified clinical experts independently evaluate analytical findings, while treating physicians retain authority over patient evaluation, diagnosis, and treatment.

03

Outcome-Independent Economics

Biopharmaceutical sponsorship funds authorized analytical services through a fair-market-value framework, independent of diagnostic findings or treatment decisions.

04

Neutral Intermediary Governance

RDDT maintains separation between commercial sponsors and clinical decision-making, protecting physician independence and patient choice.

05

Analytical Quality & Accountability

RDDT applies proprietary disease-specific methodologies and independent clinical review to deliver high-confidence suspect cohorts for further clinical consideration.

The Platform Architecture

A Five-Layer Architecture Built for Rare Disease

RDDT's platform is purpose-built for rare disease — combining secure data preparation and analysis of HCO-approved de-identified clinical information, disease-specific methodologies, independent review, and governed return of findings

01

Data Ingestion & Normalization

Secure ingestion of de-identified clinical data from healthcare organization systems, normalized across formats, specialties, and time horizons.

02

Disease-Specific Analytical Methodologies

RDDT applies independently developed disease-specific methods to authorized longitudinal information, identifying clinical signatures associated with each targeted condition.

03

Independent SME Clinical Review

Qualified clinical Subject Matter Experts evaluate every high-confidence suspect independently of biopharma sponsors before findings are returned to the healthcare organization.

04

Comprehensive Clinical Dossier & Suspect Isolate Delivery

RDDT delivers a comprehensive, unbiased clinical dossier accompanying each SME-reviewed suspect isolate, consolidating relevant longitudinal evidence, clinical indicators, and supporting findings for independent physician evaluation. The dossier presents the clinical rationale for further consideration without recommending a diagnosis or treatment.

05

HCO-Governed Clinical Evaluation

The participating healthcare organization receives the de-identified suspect findings and supporting clinical dossiers, retains exclusive control over patient re-identification, and directs all subsequent clinical evaluation. Treating physicians independently determine whether further testing, diagnosis, or treatment is appropriate.

The Economic Model

Technology Makes It Possible. Economics Makes It Happen.

Healthcare organizations operate with finite clinical and organizational capacity. Even the most powerful analytics cannot ensure that previously unsuspected rare disease patients receive the attention they deserve.

RDDT addresses that challenge through a distinctive, two-part economic model that creates sustainable value for participating healthcare organizations.

The model combines upfront compensation for authorized population-wide analysis with additional fair-market-value compensation for defined Clinical Evaluation & Reconciliation Services.

Both components are structured to support legitimate organizational activity while preserving physician independence. Compensation is not contingent on any particular diagnosis, test, treatment, or clinical outcome.

01

Upfront Compensation for Authorized Population-Wide Analysis

Pre-agreed compensation for authorized population-wide analysis using appropriately de-identified clinical information, independent of clinical findings or subsequent treatment decisions.

02

Fair-Market-Value Compensation for Defined Clinical Evaluation & Reconciliation Services

Additional compensation for defined, documented services supporting the clinical evaluation and reconciliation process, independent of diagnostic conclusions or treatment decisions.

Our innovation is not simply making invisible patients visible. It is creating the economic conditions that give healthcare organizations the capacity and reason to look.

Data Governance

Governed by Design. Secure by Architecture.

RDDT's data governance framework is not a compliance overlay — it is the foundation of the platform. Every data flow, access control, and output protocol is designed to preserve patient privacy, protect physician independence, and maintain the structural separation between healthcare organizations and biopharma sponsors.

De-identified data is analyzed within RDDT's secure environment. Patient identity remains under the healthcare organization’s control and is not disclosed to RDDT or biopharmaceutical sponsors.

Patient privacy is not a feature. It is the architecture.

The Platform Capabilities

Four Foundational Capabilities

01. Secure Clinical Data Analysis

Approved, de-identified clinical datasets are analyzed within RDDT's controlled environment, while healthcare organizations retain control of patient identity and clinical decisions.

02. Proprietary Rare Disease Intelligence

Disease-specific analytical methodologies recognize complex patterns across longitudinal clinical information that conventional approaches may overlook.

03. Independent Clinical Review

A compensation model that creates institutional value without rewarding any particular diagnosis, test, treatment, or clinical outcome — preserving physician independence and patient trust.

04. Repeatable Cycles of Analytics & Sustainability

A repeatable, sponsor-supported analytical framework enables healthcare organizations to pursue additional rare disease populations over time, creating sustained opportunities for earlier diagnosis and outcome-independent institutional revenue.

02 / THE RDDT TECHNOLOGY

The Analytical Capabilities That Make Invisible Patients Visible.

Proprietary analytical methodologies designed to surface evidence for independent clinical evaluation.

Proprietary Artificial Intelligence Application

Powerful Intelligence. Purpose-Built for Rare Disease.

RDDT applies proprietary, AI-enabled analytical methodologies to authorized, de-identified longitudinal clinical information, recognizing complex patterns and relationships that may otherwise remain obscured across years of medical encounters, specialties, and clinical records.

Its disease-specific methodologies are designed to surface previously unsuspected rare disease patients for independent clinical evaluation. By analyzing existing clinical evidence at population scale, RDDT extends the reach of clinical intelligence beyond the practical limits of conventional chart review.

RDDT's proprietary methodologies are developed independently of participating healthcare organizations' patient datasets. Authorized clinical findings and evaluation feedback may inform their ongoing refinement, subject to contractual permissions and data-governance safeguards.

Luminous digital fingerprint network representing RDDT's proprietary AI analytical methodology

AI Surfaces the Evidence. Independent Experts Evaluate. Physicians Decide.

The Confidence Model

High-Confidence Recognition. Independent Clinical Review. Measurable, Reconciled Outcomes.

RDDT's proprietary analytics surface high-confidence suspects whose longitudinal clinical records contain meaningful, multi-signal evidence of a previously unrecognized rare disease. Volume without confidence is noise. RDDT delivers signal.

Every suspect advanced for healthcare organization consideration undergoes independent, qualified Subject Matter Expert review, ensuring that analytical findings are supported by both computational rigor and clinical judgment.

But confidence is only the beginning.

RDDT's governed clinical evaluation process enables findings to be documented, measured, reported, and reconciled against subsequent clinical determinations and available claims data, including available claims information, where authorized and applicable.

Confirmed diagnoses, ruled-out suspicions, and documented clinical disagreements each contribute to an accountable record of program performance.

The result is a measurable clinical process with transparent performance reporting, documented operational performance and an evidence-based foundation for evaluating return on investment.

Measurable clinical process. Transparent performance reporting. Evidence-based return on investment.

Platform Workflow Clarity

Beyond Conventional Clinical Decision Support. A Different Operating Model.

Finding a clinical signal is not the same as creating the capacity to act on it.

Traditional EHR-based clinical decision support tools often require capital investment, technology integration, and additional physician attention. They may generate alerts, but alerts alone do not create the organizational capacity or economic incentive to pursue patients awaiting diagnosis.

RDDT was designed to solve both problems: clinical visibility and institutional capacity.

Our proprietary population-level analytics, independent specialist review, and healthcare organization-governed clinical evaluation operate within a biopharma-funded economic model. RDDT's biopharma-funded economic framework supports authorized population analytics and clinical evaluation processes through fair-market-value compensation independent of diagnostic or treatment outcomes.

This economic architecture supports institutional capacity to evaluate suspect cohorts. RDDT maintains and refines its proprietary methodologies only as permitted by applicable contracts and data-governance requirements.

No New Capital Investment for HCOs, No New EHR Alerts for Physicians, Hope for patients.

RDDT does not diagnose, prescribe, or direct care. Physicians retain complete clinical authority.

Powerful intelligence creates the capability. Clinical governance establishes the discipline. Economic architecture makes alignment sustainable.

Quality, Security & Responsible Technology Governance

Independently Validated. Built for Trust.

RDDT's technology and operating model are supported by established quality standards, independent security assessments, healthcare privacy safeguards, and responsible AI governance. These disciplines are fundamental to protecting patient information, maintaining institutional trust, and supporting secure, scalable collaboration with healthcare organizations.

ISO9001

Quality Management

Internationally recognized standards for consistent processes, operational quality, and continuous improvement.

SOC 2Type II

Security & Operational Controls

Independent assessment of security controls and their operating effectiveness over a defined review period.

HIPAA

Healthcare Privacy & Security

Privacy and security safeguards designed to protect healthcare information and support applicable regulatory and contractual obligations.

CHC

Healthcare Compliance Expertise

Professional healthcare compliance expertise supporting regulatory awareness, ethical operations, and institutional accountability.

ISO/IEC420012023

Responsible AI Management

International framework for governing artificial intelligence through structured risk management, accountability, oversight, and continuous improvement.

"The true measure of innovation in healthcare is not the sophistication of the technology we create, but the difference it makes in people's lives"

J. Mark Tumblin PhD, Chief Technology Officer RDDT

Technology Serving Humanity

Powerful intelligence is the capability. Clinical governance is the discipline. RDDT's operating model is what brings them together for patients.

They are not rare because they do not exist. They are rare because they have not been found. RDDT exists to change that — for patients, for healthcare organizations, and for the biopharmaceutical companies developing the therapies that can help them.

If your organization is ready to explore what a governed, compliant, economically sustainable rare disease visibility program could look like, we would welcome the conversation.

Contact Us